Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis

Immune checkpoint inhibitors (ICIs) have been increasingly applied in the treatment of several kinds of malignancies. Some clinical demographic characteristics were reported to be associated with the ICIs efficacy. The purpose of our current meta-analysis was to clearly evaluated the relationship be...

Full description

Saved in:
Bibliographic Details
Published in:Journal of translational medicine 2020-06, Vol.18 (1), p.235-235, Article 235
Main Authors: An, Yue, Wu, Zhonghua, Wang, Ningning, Yang, Zhidong, Li, Yue, Xu, Boyang, Sun, Mingjun
Format: Article
Language:English
Subjects:
Analysis
Atezolizumab
Avelumab
Biomarkers
Body Mass Index
Body weight
Cancer
Cancer patients
Cancer therapies
Drug therapy
Drug-Related Side Effects and Adverse Reactions
Durvalumab
Humans
Immune Checkpoint Inhibitors
Immunotherapy
Ipilimumab
Medical prognosis
Medical research
Melanoma
Meta-analysis
Neoplasms - complications
Neoplasms - drug therapy
Nivolumab
Obesity
Oncology
Overall survival
Overweight
Patient outcomes
Patients
Pembrolizumab
Progression-free survival
Quality
Studies
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune checkpoint inhibitors (ICIs) have been increasingly applied in the treatment of several kinds of malignancies. Some clinical demographic characteristics were reported to be associated with the ICIs efficacy. The purpose of our current meta-analysis was to clearly evaluated the relationship between BMI and ICIs efficacy for cancer patients receiving immunotherapy. A systematic search of Pubmed, EMBASE and conference proceedings was performed to investigate the influence of BMI on ICIs efficacy. Pooled analysis for overall survival (OS), progression-free survival (PFS) and immune-related adverse effects (IRAEs) were analyzed in current study. A total of 13 eligible studies comprising 5279 cancer patients treated with ICIs were included in the analysis. The pooled analysis showed there is positive association between high BMI and improved OS and PFS among patients with ICIs treatment (OS: HR = 0.62, 95% CI 0.55-0.71, P 
ISSN:1479-5876
1479-5876
DOI:10.1186/s12967-020-02404-x